File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer

TitleA phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer
Authors
Issue Date2011
Citation
Clinical Colorectal Cancer, 2011, v. 10 n. 3, p. 210-216 How to Cite?
AbstractBackground: This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer. Patients and Methods: Nineteen patients with previously untreated advanced colorectal cancer received capecitabine at 1000 mg/m 2 twice a day on days 1-5 and days 8-12 of a 14-day cycle, and OHP at 85 mg/m 2 and bevacizumab at 10 mg/kg every 2 weeks. Because of unacceptable toxicities, the capecitabine dose was reduced to 850 mg/m 2. Thirty-one additional patients were treated at the lower capecitabine dose. Treatment continued until disease progression, persistent intolerable toxicity, or physician and/or patient discretion. Results: Overall, toxicities were better managed and tolerated at the 850 mg/-m 2 capecitabine dose. The most common treatment-related grade < 3 toxicities were diarrhea and sensory neuropathy. In the first 19 subjects, the response rate was 63% (95% confidence interval [CI], 38%-84%) and 5 patients had stable disease; median progression-free survival (PFS) was 10.1 months (95% CI, 5.7-19.5 months). In the subsequent 31 patients, the response was 42% (95% CI, 25%-61%); 11 patients had stable disease and median PFS was 10.4 months (95% CI, 6.9-15.4); median overall survival was 24.8 months (95% CI, 12.9-39.7). Conclusions: This novel regimen of capecitabine at 850 mg/m 2 twice a day on days 1-5 and days 8-12 and OHP at 85 mg/m 2and bevacizumab at 10 mg/kg every 14 days is clinically active in advanced colorectal cancer. The toxicity profile of this regimen is consistent with the standard every-3-week dosing schedule. © 2011 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/194321
ISSN
2015 Impact Factor: 3.09
2015 SCImago Journal Rankings: 1.382
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, NS-
dc.contributor.authorFernando, NH-
dc.contributor.authorBendell, JC-
dc.contributor.authorMorse, MA-
dc.contributor.authorBlobe, GC-
dc.contributor.authorHoneycutt, W-
dc.contributor.authorPang, H-
dc.contributor.authorHurwitz, HI-
dc.date.accessioned2014-01-30T03:32:27Z-
dc.date.available2014-01-30T03:32:27Z-
dc.date.issued2011-
dc.identifier.citationClinical Colorectal Cancer, 2011, v. 10 n. 3, p. 210-216-
dc.identifier.issn1533-0028-
dc.identifier.urihttp://hdl.handle.net/10722/194321-
dc.description.abstractBackground: This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer. Patients and Methods: Nineteen patients with previously untreated advanced colorectal cancer received capecitabine at 1000 mg/m 2 twice a day on days 1-5 and days 8-12 of a 14-day cycle, and OHP at 85 mg/m 2 and bevacizumab at 10 mg/kg every 2 weeks. Because of unacceptable toxicities, the capecitabine dose was reduced to 850 mg/m 2. Thirty-one additional patients were treated at the lower capecitabine dose. Treatment continued until disease progression, persistent intolerable toxicity, or physician and/or patient discretion. Results: Overall, toxicities were better managed and tolerated at the 850 mg/-m 2 capecitabine dose. The most common treatment-related grade < 3 toxicities were diarrhea and sensory neuropathy. In the first 19 subjects, the response rate was 63% (95% confidence interval [CI], 38%-84%) and 5 patients had stable disease; median progression-free survival (PFS) was 10.1 months (95% CI, 5.7-19.5 months). In the subsequent 31 patients, the response was 42% (95% CI, 25%-61%); 11 patients had stable disease and median PFS was 10.4 months (95% CI, 6.9-15.4); median overall survival was 24.8 months (95% CI, 12.9-39.7). Conclusions: This novel regimen of capecitabine at 850 mg/m 2 twice a day on days 1-5 and days 8-12 and OHP at 85 mg/m 2and bevacizumab at 10 mg/kg every 14 days is clinically active in advanced colorectal cancer. The toxicity profile of this regimen is consistent with the standard every-3-week dosing schedule. © 2011 Elsevier Inc. All rights reserved.-
dc.languageeng-
dc.relation.ispartofClinical Colorectal Cancer-
dc.titleA phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.clcc.2011.03.018-
dc.identifier.pmid21855046-
dc.identifier.scopuseid_2-s2.0-80052456693-
dc.identifier.volume10-
dc.identifier.issue3-
dc.identifier.spage210-
dc.identifier.epage216-
dc.identifier.isiWOS:000294157100012-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats